$CAPR,,,Keep your eyes on this stock,,lots of news and lots of inside purchases as well all institutional buys,,,here is only one article from Friday:
Capricor Therapeutics Inc (CAPR) Major Shareholder Sinai Medical Center Cedars Buys 1,145,161 Shares
May 12th, 2017 - By Doug Wharley - 0 comments
Capricor Therapeutics logoCapricor Therapeutics Inc (OTCMKTS:CAPR) major shareholder Sinai Medical Center Cedars acquired 1,145,161 shares of the company’s stock in a transaction that occurred on Tuesday, May 9th. The stock was acquired at an average price of $3.10 per share, with a total value of $3,549,999.10. Following the acquisition, the insider now owns 4,049,959 shares in the company, valued at $12,554,872.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Capricor Therapeutics Inc (OTCMKTS:CAPR) traded down 61.97% on Friday, reaching $1.16. 1,962,389 shares of the company’s stock traded hands. Capricor Therapeutics Inc has a 12 month low of $1.13 and a 12 month high of $5.40. The firm’s market cap is $24.82 million. The firm’s 50-day moving average is $3.14 and its 200 day moving average is $2.87.
Get Capricor Therapeutics Inc alerts:
Capricor Therapeutics (OTCMKTS:CAPR) last announced its earnings results on Wednesday, March 15th. The biotechnology company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.16. The business had revenue of $0.91 million for the quarter, compared to the consensus estimate of $1.05 million. Equities analysts predict that Capricor Therapeutics Inc will post ($0.74) EPS for the current year.
Several research analysts have issued reports on the stock. HC Wainwright set a $14.00 price target on shares of Capricor Therapeutics and gave the stock a “buy” rating in a report on Thursday, March 16th. Zacks Investment Research upgraded shares of Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a report on Monday, April 17th. Finally, Rodman & Renshaw assumed coverage on shares of Capricor Therapeutics in a report on Monday, February 13th. They set a “buy” rating and a $14.00 price target for the company.
An institutional investor recently raised its position in Capricor Therapeutics stock. Geode Capital Management LLC raised its position in shares of Capricor Therapeutics Inc (OTCMKTS:CAPR) by 5.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,387 shares of the biotechnology company’s stock after buying an additional 2,458 shares during the period. Geode Capital Management LLC’s holdings in Capricor Therapeutics were worth $154,000 as of its most recent SEC filing.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.
Capricor Therapeutics Inc (CAPR) Major Shareholder Sinai Medical Center Cedars Buys 1,145,161 Shares
May 12th, 2017 - By Doug Wharley - 0 comments
Capricor Therapeutics logoCapricor Therapeutics Inc (OTCMKTS:CAPR) major shareholder Sinai Medical Center Cedars acquired 1,145,161 shares of the company’s stock in a transaction that occurred on Tuesday, May 9th. The stock was acquired at an average price of $3.10 per share, with a total value of $3,549,999.10. Following the acquisition, the insider now owns 4,049,959 shares in the company, valued at $12,554,872.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Capricor Therapeutics Inc (OTCMKTS:CAPR) traded down 61.97% on Friday, reaching $1.16. 1,962,389 shares of the company’s stock traded hands. Capricor Therapeutics Inc has a 12 month low of $1.13 and a 12 month high of $5.40. The firm’s market cap is $24.82 million. The firm’s 50-day moving average is $3.14 and its 200 day moving average is $2.87.
Get Capricor Therapeutics Inc alerts:
Capricor Therapeutics (OTCMKTS:CAPR) last announced its earnings results on Wednesday, March 15th. The biotechnology company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.16. The business had revenue of $0.91 million for the quarter, compared to the consensus estimate of $1.05 million. Equities analysts predict that Capricor Therapeutics Inc will post ($0.74) EPS for the current year.
Several research analysts have issued reports on the stock. HC Wainwright set a $14.00 price target on shares of Capricor Therapeutics and gave the stock a “buy” rating in a report on Thursday, March 16th. Zacks Investment Research upgraded shares of Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a report on Monday, April 17th. Finally, Rodman & Renshaw assumed coverage on shares of Capricor Therapeutics in a report on Monday, February 13th. They set a “buy” rating and a $14.00 price target for the company.
An institutional investor recently raised its position in Capricor Therapeutics stock. Geode Capital Management LLC raised its position in shares of Capricor Therapeutics Inc (OTCMKTS:CAPR) by 5.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,387 shares of the biotechnology company’s stock after buying an additional 2,458 shares during the period. Geode Capital Management LLC’s holdings in Capricor Therapeutics were worth $154,000 as of its most recent SEC filing.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.
1
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280
